Prescient Therapeutics (ASX:PTX) secured authorization from the European Clinical Trials Information System to begin its clinical trial for cancer drug candidate PTX-100 in patients with relapsed/refractory cutaneous T-cell lymphoma in Italy, according to a Monday filing with the Australian bourse.

The approval enables the activation of trial sites and patient recruitment for the phase 2A study in Europe, the filing said.

Shares rose 9% in afternoon trade on Monday and earlier reached their highest since April 2023.